Guggenheim analyst Louise Chen reiterated a Buy rating and raised her price target on Actavis (NYSE: ACT) to $345.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change

Actavis (ACT) PT Lifted to $340 at ArgusFebruary 20, 2015 9:32 AM Actavis (ACT) PT Lifted to $352 at Canaccord GenuityFebruary 19, 2015 7:55 AM Actavis (ACT) Announces $8.4B Ordinary, Convertible Preferred Share OfferingFebruary 19, 2015 7:39 AM Actavis (ACT) to Adopt 'Allergan' NameFebruary 18, 2015 7:04 AM Actavis (ACT) Updates on Key Pipeline Program, Potential Market OpportunitiesFebruary 18, 2015 6:47 AM Actavis (ACT) Reports In-Line Q4 EPS; Guides FY15 EPS, RevsFebruary 18, 2015 6:32 AM Paulson & Co. Shows New Stakes in Salix Pharmaceuticals (SLXP), Spansion (SPAN), Talisman (TLM); Exits AbbVie (ABBV) (more...) February 17, 2015 5:25 PM Actavis (ACT) Reports Temporary Injunction on Generic Pulmicort RESPULESFebruary 17, 2015 5:23 PM